MX2022016365A - Formulacion de alta concentracion de proteinas de union a antigeno de factor xii. - Google Patents
Formulacion de alta concentracion de proteinas de union a antigeno de factor xii.Info
- Publication number
- MX2022016365A MX2022016365A MX2022016365A MX2022016365A MX2022016365A MX 2022016365 A MX2022016365 A MX 2022016365A MX 2022016365 A MX2022016365 A MX 2022016365A MX 2022016365 A MX2022016365 A MX 2022016365A MX 2022016365 A MX2022016365 A MX 2022016365A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen binding
- factor xii
- formulation
- high concentration
- binding proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20184004 | 2020-07-03 | ||
| PCT/AU2021/050714 WO2022000046A1 (en) | 2020-07-03 | 2021-07-05 | High concentration formulation of factor xii antigen binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016365A true MX2022016365A (es) | 2023-01-30 |
Family
ID=71514949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016365A MX2022016365A (es) | 2020-07-03 | 2021-07-05 | Formulacion de alta concentracion de proteinas de union a antigeno de factor xii. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240277839A1 (enExample) |
| EP (1) | EP4175669A4 (enExample) |
| JP (1) | JP7880827B2 (enExample) |
| KR (1) | KR20230035355A (enExample) |
| CN (1) | CN116322764A (enExample) |
| AU (1) | AU2021302684A1 (enExample) |
| BR (1) | BR112022026482A2 (enExample) |
| CA (1) | CA3183508A1 (enExample) |
| CL (1) | CL2023000004A1 (enExample) |
| IL (1) | IL298989A (enExample) |
| MX (1) | MX2022016365A (enExample) |
| WO (1) | WO2022000046A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4337257A1 (en) * | 2021-05-12 | 2024-03-20 | AnaptysBio, Inc. | Antibody composition |
| US20250042984A1 (en) * | 2021-12-20 | 2025-02-06 | CSL Innovation Pty Ltd | Protein formulations and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20250164T1 (hr) | 2011-07-22 | 2025-04-11 | Csl Behring Gmbh | Inhibitorna monoklonska antitijela protiv faktora xii/xiia i njihove uporabe |
| JP5859148B2 (ja) * | 2012-03-08 | 2016-02-10 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Aβ抗体製剤 |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| EP3325516B1 (en) * | 2015-07-21 | 2021-12-15 | Takeda Pharmaceutical Company Limited | A monoclonal antibody inhibitor of factor xiia |
| EP3433274A1 (en) * | 2016-03-25 | 2019-01-30 | Visterra, Inc. | Formulation of antibody molecules to dengue virus |
| EP3440107A4 (en) * | 2016-04-06 | 2020-02-19 | CSL Limited | METHOD FOR TREATING ATHEROSCLEROSIS |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| BR112019011900A2 (pt) | 2016-12-23 | 2019-11-26 | Serum Institute Of India Private Limited | métodos melhorados para aumentar a produtividade de anticorpos na cultura de células de mamíferos e minimizar a agregação durante os processos downs-tream, processos de formulação, e formulações de anticorpos estáveis obtidas dos mesmos |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| EA202190056A1 (ru) * | 2018-06-19 | 2021-05-28 | Ридженерон Фармасьютикалз, Инк. | АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ |
| US12134657B2 (en) | 2018-11-28 | 2024-11-05 | Oregon Health & Science University | Therapeutic factor XII antibody |
| US20230390418A1 (en) * | 2020-10-29 | 2023-12-07 | Regenxbio Inc. | Vectorized factor xii antibodies and administration thereof |
-
2021
- 2021-07-05 IL IL298989A patent/IL298989A/en unknown
- 2021-07-05 EP EP21834598.1A patent/EP4175669A4/en active Pending
- 2021-07-05 BR BR112022026482A patent/BR112022026482A2/pt unknown
- 2021-07-05 MX MX2022016365A patent/MX2022016365A/es unknown
- 2021-07-05 US US18/004,004 patent/US20240277839A1/en active Pending
- 2021-07-05 KR KR1020237003982A patent/KR20230035355A/ko active Pending
- 2021-07-05 JP JP2022581380A patent/JP7880827B2/ja active Active
- 2021-07-05 CN CN202180053399.8A patent/CN116322764A/zh active Pending
- 2021-07-05 WO PCT/AU2021/050714 patent/WO2022000046A1/en not_active Ceased
- 2021-07-05 AU AU2021302684A patent/AU2021302684A1/en active Pending
- 2021-07-05 CA CA3183508A patent/CA3183508A1/en active Pending
-
2023
- 2023-01-03 CL CL2023000004A patent/CL2023000004A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022000046A1 (en) | 2022-01-06 |
| CA3183508A1 (en) | 2022-01-06 |
| KR20230035355A (ko) | 2023-03-13 |
| CL2023000004A1 (es) | 2023-08-25 |
| AU2021302684A1 (en) | 2023-02-23 |
| EP4175669A1 (en) | 2023-05-10 |
| BR112022026482A2 (pt) | 2023-01-31 |
| JP7880827B2 (ja) | 2026-06-26 |
| US20240277839A1 (en) | 2024-08-22 |
| EP4175669A4 (en) | 2025-11-12 |
| JP2023531315A (ja) | 2023-07-21 |
| CN116322764A (zh) | 2023-06-23 |
| IL298989A (en) | 2023-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2569409T3 (es) | Composiciones de anticuerpo anti-CTLA-4 | |
| EA200870538A1 (ru) | Лиофилизированные композиции анти-egfr антител | |
| EA201992377A1 (ru) | Стабильная композиция антитела | |
| RU2013137740A (ru) | Жидкая композиция, содержащая антитело высокой концентрации | |
| EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
| MX2024000901A (es) | Composiciones y metodos para la degradacion selectiva de proteinas dise?adas por ingenieria. | |
| EA201992613A1 (ru) | Фармацевтическая композиция, содержащая конструкции на основе биспецифического антитела, обеспечивающая улучшенное хранение и введение | |
| EA200970880A1 (ru) | Стабильные композиции на основе антител | |
| AR079836A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r) | |
| RU2011142184A (ru) | Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами | |
| EP4233892A3 (en) | Stable anti-ifnar1 formulation | |
| EA201790989A1 (ru) | Стабильный препарат раствора белка, содержащего анти-vegf антитело в высокой концентрации | |
| CL2023000004A1 (es) | Formulación en concentración alta de proteínas de unión a antígeno del factor xii | |
| BRPI0514340A (pt) | formulações de estabilização | |
| MX2021007393A (es) | Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf. | |
| PH12022551618A1 (en) | Programmed cell death receptor 1 antibody formulation and use thereof | |
| WO2021050009A3 (en) | Composition of renaturation buffer solution for dimeric proteins and method of renaturation dimeric proteins using the composition thereof | |
| Shiraki et al. | Amino acid esters prevent thermal inactivation and aggregation of lysozyme | |
| CN108409852B (zh) | 性激素结合球蛋白保存液以及其应用 | |
| MX2025010514A (es) | Formulaciones de proteínas de alta concentración con excipientes de polisorbato y métodos para fabricarlas | |
| AR128795A1 (es) | FORMULACIÓN LIOFILIZADA QUE COMPRENDE UNA PROTEÍNA DE FUSIÓN QUE INCLUYE a-GALACTOSIDASA A | |
| JOP20240024A1 (ar) | صياغات الأجسام المضادة | |
| JP2021521168A5 (enExample) | ||
| Huang et al. | Protein covalent dimer formation induced by reversed‐phase HPLC conditions | |
| PE20241936A1 (es) | Formulaciones que comprenden fab-peg |